Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carperitide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPR1 known ✓ | P16066 | 1/20 | 0.94 |
| ▸ | NPR3 known ✓ | P17342 | 1/20 | 0.94 |
| ▸ | MC4R | P32245 | 2/20 | 0.59 |
| ▸ | MC1R | Q01726 | 2/20 | 0.59 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.56 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.56 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.56 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | F11 | P03951 | 2/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | MC3R | P41968 | 1/20 | 0.54 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.53 |
| ▸ | RXFP4 | Q8TDU9 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376235 | 0.97 | NPR1 (0.88) | NPR1NPR3MC4RMC1RCSNK2A2 | |
| Acetic Acid SCHEMBL29363649 | 0.96 | NPR1 (0.87) | NPR1NPR3MC4RMC1RKCNA3 | |
| SCHEMBL29711548 | 0.96 | NPR1 (0.86) | NPR1NPR3MC4RMC1RKCNA3 | |
| Hydrochloric Acid SCHEMBL29495482 | 0.95 | NPR1 (0.85) | NPR1NPR3MC4RMC1RKCNA3 | |
| Ularitide SCHEMBL29484210 | 0.92 | NPR1 (0.79) | NPR1NPR3MC4RMC1RKCNA3 | |
| Ularitide SCHEMBL27908491 | 0.92 | NPR1 (0.79) | NPR1NPR3MC4RMC1RKCNA3 | |
| SCHEMBL31332082 | 0.91 | NPR1 (0.78) | NPR1NPR3MC4RMC1RKCNA3 | |
| SCHEMBL29379928 | 0.91 | NPR1 (0.78) | NPR1NPR3MC4RMC1RKCNA3 | |
| SCHEMBL29689331 | 0.90 | NPR1 (0.77) | NPR1NPR3MC4RMC1RKCNA3 | |
| Ularitide SCHEMBL29357163 | 0.86 | NPR1 (0.71) | NPR1NPR3MC4RMC1RKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2396 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3781315-B1 | MICROFLUIDIC METHOD FOR SINGLE CELL ANALYSIS | HIFIBIO SAS (FR) | 2026-01-14 | — | — | EP | claimed |
| US-12521722-B2 | Microfluidic method for single cell analysis | HIFIBIO SAS (FR) | 2026-01-13 | — | — | US | claimed |
| US-12491258-B2 | Method for preparing long-acting drug conjugate through preparation of intermediate | HANMI PHARM. CO., LTD. (KR) | 2025-12-09 | — | — | US | claimed |
| EP-4062917-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250297031-A1 | HUMAN FC VARIANTS HAVING IMPROVED FCGRIIA BINDING SELECTIVITY | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2025-09-25 | — | — | US | claimed |
| EP-4608396-A1 | TREATMENT OF IGA NEPHROPATHY USING AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN APRIL BINDING ANTIBODY | Chinook Therapeutics, Inc. (US) | 2025-09-03 | — | — | EP | claimed |
| US-12390533-B2 | Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor | HANMI PHARM. CO., LTD. (KR) | 2025-08-19 | — | — | US | claimed |
| WO-2008141189-A1 | GHRELIN MODULATING COMPOUNDS AND COMBINATIONS THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20050181066-A1 | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | US | claimed |
| EP-1501605-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA Pharma AG (DE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003090870-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | claimed |